The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Shares of Bristol Myers BMY have lost 20.7% in the past three months compared with the industry ’s decline of 9.6%. The stock ...

Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's ...

Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse ...

Also Read: Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use ... aficamten and continue to expect a differentiated label and risk mitigation profile upon its potential ...

In the U.S., Camzyos can only be used ... and continue to expect a differentiated label and risk mitigation profile upon its potential approval by FDA,” said Robert Blum, Cytokinetics ...

H.C. Wainwright maintained its Buy rating and a higher price target of $120, expressing optimism about aficamten’s prospects following label updates to a competitor’s drug, Camzyos.

Eligible patients taking Camzyos in the maintenance phase now only require twice-yearly echocardiogram monitoring. The Food and Drug Administration (FDA) has updated the labeling for Camzyos ® ...

FDA lowers echo monitoring to every 6 months for select Camzyos patients in maintenance phase. Camzyos label update removes prior contraindications with certain CYP inhibitors. Get stock picks ...

The FDA has updated the US prescribing information for ... 1 “In addition to the established efficacy of Camzyos, these meaningful updates to the label reinforce the strong safety profile of the ...

Bristol Myers (BMY) Squibb announced that the U.S. Food and Drug Administration ... to the established efficacy of Camzyos, these meaningful updates to the label reinforce the strong safety ...